Abstract
Chemical castration improves responses to radiotherapy in prostate cancer, but the mechanism is unknown. We hypothesized that this radiosensitization is caused by castration-mediated down-regulation of nonhomologous end joining (NHEJ) repair of DNA double-strand breaks (DSBs). To test this, we enrolled 48 patients with localized prostate cancer in two arms of the study: either radiotherapy first or radiotherapy after neoadjuvant castration treatment. We biopsied patients at diagnosis and before and after castration and radiotherapy treatments to monitor androgen receptor, NHEJ, and DSB repair in verified cancer tissue. We show that patients receiving neoadjuvant castration treatment before radiotherapy had reduced amounts of the NHEJ protein Ku70, impaired radiotherapy-induced NHEJ activity, and higher amounts of unrepaired DSBs, measured by γ-H2AX foci in cancer tissues. This study demonstrates that chemical castration impairs NHEJ activity in prostate cancer tissue, explaining the improved response of patients with prostate cancer to radiotherapy after chemical castration.
MeSH Terms
Adult
Aged
Aged, 80 and over
DNA Breaks, Double-Stranded
DNA Repair Enzymes/genetics
DNA-Binding Proteins/genetics
Gene Expression Regulation, Neoplastic
Histones/genetics
Humans
Male
Middle Aged
Orchiectomy
Prostatic Neoplasms/genetics,physiopathology,radiotherapy
Radiation Tolerance
Radiation-Sensitizing Agents/pharmacology,therapeutic use
Receptors, Androgen/genetics
Young Adult
Chemicals
AR protein, human
DNA-Binding Proteins
H2AX protein, human
Histones
NHEJ1 protein, human
Radiation-Sensitizing Agents
Receptors, Androgen
DNA Repair Enzymes
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Tarish Firas L
Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 65 Stockholm, Sweden. Department of Urology, Central Hospital, 721 89 Västerås, Sweden.
Schultz Niklas
Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 65 Stockholm, Sweden.
Tanoglidi Anna
Department of Clinical Pathology, Uppsala University Hospital, 751 85 Uppsala, Sweden.
Hamberg Hans
Department of Pathology, Central Hospital, 721 89 Västerås, Sweden.
Letocha Henry
Department of Oncology, Central Hospital, 721 89 Västerås, Sweden.
Karaszi Katalin
Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, OX3 9DU Oxford, UK.
Hamdy Freddie C
Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, OX3 9DU Oxford, UK.
Granfors Torvald
Department of Urology, Central Hospital, 721 89 Västerås, Sweden.
Helleday Thomas
Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 65 Stockholm, Sweden. thomas.helleday@scilifelab.se.